Clicky

Fresh Tracks Therapeutics(FRTX)

Description: Fresh Tracks Therapeutics, Inc. is a clinical-stage pharmaceutical company striving to transform patient lives through the development of innovative and differentiated prescription therapeutics. The Company’s pipeline aims to disrupt existing treatment paradigms and features several new molecular entities that inhibit novel targets with first-in-class potential for autoimmune, inflammatory, and other debilitating diseases. Fresh Track Therapeutic’s executive management team and board of directors have a proven track record of leadership across early-stage research, product development, and global commercialization, having served in leadership roles at large global pharmaceutical and biotech companies that successfully developed and/or launched first-in-class products that achieved iconic status, including Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta®, Juvederm®, Pluvicto®, and Sofpironium Bromide. The Company’s strategy is to align this experience and clear vision to explore beyond the limitations of current therapies by identifying, pursuing, and developing next-generation therapeutics that can be groundbreaking in their ability to help millions of people struggling with autoimmune, inflammatory, and other debilitating diseases.


Keywords: Biotechnology Pharmaceutical Life Sciences Disease Inflammatory Cialis Cymbalta

Home Page: www.frtx.com

FRTX Technical Analysis

5777 Central Avenue
Boulder, CO 80301
United States
Phone: 720 505 4755


Officers

Name Title
Mr. Reginald L. Hardy M.B.A., R.Ph. Co-Founder & Chairman
Attorney Robert Busard Brown CEO & Director
Mr. Andrew D. Sklawer Co-Founder, Pres & Sec.
Mr. Deepak Chadha M.B.A., M.S., MBA, MS, RAC Chief R&D Officer and COO
Mr. Albert Nicholas Marchio II CFO and Principal Accounting & Financial Officer
Mr. David R. Mcavoy J.D. Gen. Counsel & Chief Compliance Officer
Mr. Gary S. Walker Chief Marketing Officer
Aron Aizenstat M.B.A., P.M.P. VP of Corp. Devel. & Operations
Ms. Sue Fattor Head of Human Resource
Ms. Nancy Seretta VP & Head of Clinical Operations

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0.392
Price-to-Sales TTM: 0.8623
IPO Date: 2022-09-08
Fiscal Year End: December
Full Time Employees: 16
Back to stocks